Inflammatory Gene Panel for Early Disease and Treatment Response Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods fail to accurately diagnose and monitor chronic inflammatory diseases and evaluate treatment responses due to the elusive nature of early inflammatory reactions, particularly in conditions like heart attacks, sudden cardiac death, preeclampsia, cancer, diabetes, and autoimmune disorders, where inflammation is a common underlying cause.
Innovation Solution
A method involving the measurement of mRNA levels of specific genes and protein biomarkers, such as KRT1, CCL27, SDK1, PPARG, IL1A, SMAD3, SLC6A3, NR3C1, KRT83, HFE2, CASP3, CACNA1C, NFKB2, CASP9, and CASP9, or combinations thereof, to determine the presence of bladder, colon, or breast cancer, and chronic inflammatory diseases, and assess treatment response by comparing expression levels before and after treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods are used, then the diagnostic process is simple and quick, but the accuracy of detecting early inflammatory reactions is low
Solution Approach 1:
The diagnostic method is segmented into multiple components: a panel of specific biomarkers (CRP, IL-6, TNF-alpha, etc.) is selected to detect different aspects of inflammatory response. This segmentation allows comprehensive detection of early inflammatory reactions through multiple specific indicators rather than relying on a single complex test.
Solution Approach 2:
The biomarker panel serves multiple functions simultaneously: it detects early inflammatory reactions, monitors disease progression, evaluates treatment responses, and applies to various inflammatory conditions (cardiovascular diseases, diabetes, cancer, autoimmune disorders). This multi-functionality improves detection accuracy without proportionally increasing complexity.
2Reliability
If comprehensive biomarker panels are used, then the accuracy of disease diagnosis is improved, but the complexity of the diagnostic method increases
Solution Approach 1:
The method focuses on measuring specific parameters (expression levels of selected biomarkers) rather than comprehensive genomic analysis. By changing from a broad approach to targeted measurement of key inflammatory markers, the system achieves high diagnostic reliability while maintaining manageable complexity through standardized quantification protocols.
Solution Approach 2:
The patent uses mRNA expression levels as intermediary indicators that reflect protein biomarker levels. This intermediary measurement approach allows indirect assessment of inflammatory status with simpler techniques compared to direct protein measurement, improving reliability while controlling complexity through established molecular biology methods.
3Measurement precision
If multiple biomarkers are measured to evaluate treatment response, then the evaluation accuracy is improved, but the time and resources required increase
Solution Approach 1:
The method establishes baseline biomarker levels before treatment initiation and uses this preliminary data for comparison. By preparing reference values in advance and having standardized measurement protocols ready, the system can quickly evaluate treatment responses without repeating extensive diagnostic work, thus improving accuracy while minimizing time loss.
Solution Approach 2:
The patent implements a feedback mechanism where biomarker levels are measured at multiple time points (baseline, during treatment, after treatment) and compared to assess treatment efficacy. This systematic feedback approach provides accurate evaluation of treatment response over time while using efficient longitudinal comparison rather than repeated comprehensive diagnostics.
Data Source
AI summary
Provided is a method of determining whether a patient has bladder cancer, colon cancer, or breast cancer. Also provided is a method of determining whether a patient has a chronic inflammatory disease. Additionally provided is a method of evaluating patient response to a treatment for a chronic inflammatory disease. Further provided is a method of developing a treatment for a chronic inflammatory disease in a patient.